Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients

NCT03874000 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
43
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators